Beta-glucans in the treatment of diabetes and associated cardiovascular risks

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1265-1272

  Chen, Jiezhong ^a,c   Raymond, Kenneth ^b  

^a Australian National University   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c UNIVERSITY OF CANBERRA   (Australia)

Author keywords

Diabetes mellitus; Hyperglycemia; Pathogenesis; Prevalence

Indexed keywords

BETA GLUCAN; DECTIN 1; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIETARY INTAKE; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; NONHUMAN; OBESITY; PATHOGENESIS; RECEPTOR BINDING; REVIEW; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

BETA-GLUCANS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; RISK FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 60249103856     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Alminger M, Eklund-Jonsson C. 2008. Whole-grain cereal products based on a high-fibre barley or oat genotype lower post-prandial glucose and insulin responses in healthy humans. Eur J Nutr, 47:294-300.
2. Anai M, Funaki M, Ogihara T, et al. 1998. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes, 47:13-23.
3. Anderson JW. 1995 Dietary fibre, complex carbohydrate and coronary artery disease. Can J Cardiol, 11(Suppl G):55G-62G.
4. Anderson JW, Deakins DA, Floore TL, et al. 1990. Dietary fiber and coronary heart disease. Crit Rev Food Sci Nutr, 29:95-147.
5. Anderson JW, Gilinsky NH, Deakins DA, et al. 1991. Lipid responses of hypercholesterolemic men to oat-bran and wheat-bran intake. Am J Clin Nutr, 54:678-83.
6. Artiss JD, Brogan K, Brucal M, et al. 2006. The effects of a new soluble dietary fiber on weight gain and selected blood parameters in rats. Metabolism, 55:195-202.
7. Asano T, Fujishiro M, Kushiyama A, et al. 2007. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol Pharm Bull, 30:1610-6.
8. Assmann G, Schulte H, Cullen P. 1997. New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res, 2:237-42.
9. Behall KM, Scholfield DJ, Hallfrisch J. 2004. Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women. Am J Clin Nutr, 80:1185-93.
10. Berdal M, Appelbom HI, Eikrem JH, et al. 2007. Aminated beta-1,3-D-glucan improves wound healing in diabetic db/db mice. Wound Repair Regen, 15:825-32.
11. Bertoni AG, Tsai A, Kasper EK, et al. 2003. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care, 26:2791-5.
12. Browder W, Williams D, Lucore P, et al. 1988. Effect of enhanced macrophage function on early wound healing. Surgery, 104:224-30.
13. Brown GD. 2006. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol, 6:33-43.
14. Carpenter MW. 2007. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care, 30(Suppl 2):S246-50.
15. Chen J. 2008. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nat Clin Pract Gastroenterol Hepatol, 5:306-7.
16. Chen J, McMillan NA. 2008. Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia. Cancer Biol Ther, 7:174-9.
17. Chen J, Seviour R. 2007. Medicinal importance of fungal beta-(1→3), (1→6)-glucans. Mycol Res, 111:635-52.
18. Colhoun HM, Betteridge DJ, Durrington PN, et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364:685-96.
19. Collins R, Armitage J, Parish S, et al. 2003. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 361:2005-16.
20. Czech MP, Corvera S. 1999. Signaling mechanisms that regulate glucose transport. J Biol Chem, 274:1865-8.
21. Davidson MH, Dugan LD, Burns JH, et al. 1991. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran. A dose-controlled study. JAMA, 265:1833-9.
22. Davy BM, Davy KP, Ho RC, et al. 2002. High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middle-aged and older men. Am J Clin Nutr, 76:351-8.
23. Denke MA, Sempos CT, Grundy SM. 1994. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch Intern Med, 154:401-10.
24. Domanski M, Krause-Steinrauf H, Deedwania P, et al. 2003. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol, 42:914-22.
25. Drzikova B, Dongowski G, Gebhardt E. 2005. Dietary fibre-rich oat-based products affect serum lipids, microbiota, formation of short-chain fatty acids and steroids in rats. Br J Nutr, 94:1012-25.
26. Ellegard L, Andersson H. 2007. Oat bran rapidly increases bile acid excretion and bile acid synthesis: an ileostomy study. Eur J Clin Nutr, 61:938-45.
27. Faraj M, Lu HL, Cianflone K. 2004. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol, 82:170-90.
28. Folli F, Saad MJ, Backer JM, et al. 1993. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest, 92:1787-94.
29. Fox CS, Coady S, Sorlie PD, et al. 2004. Trends in cardiovascular complications of diabetes. JAMA, 292:2495-9.
30. Fox CS, Pencina MJ, Meigs JB, et al. 2006. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation, 113:2914-8.
31. Frank RN. 2004. Diabetic retinopathy. N Engl J Med, 350:48-58.
32. Frustaci A, Kajstura J, Chimenti C, et al. 2000. Myocardial cell death in human diabetes. Circ Res, 87:1123-32.
33. Gabbay RA, Sutherland C, Gnudi L, et al. 1996. Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem, 271:1890-7.
34. Gerhardt AL, Gallo NB. 1998 Full-fat rice bran and oat bran similarly reduce hypercholesterolemia in humans. J Nutr, 128:865-9.
35. Goff DC Jr, Gerstein HC, Ginsberg HN, et al. 2007. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol, 99:4i-20i.
36. Greenhalgh DG, Sprugel KH, Murray MJ, et al. 1990. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol, 136:1235-46.
37. Gross JL, De Azevedo MJ, Silveiro SP, et al. 2005. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care, 28:164-76.
38. Haffner SM, Lehto S, Ronnemaa T, et al. 1998. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339:229-34.
39. Han KH, Sekikawa M, Shimada K, et al. 2004. Resistant starch fraction prepared from kintoki bean affects gene expression of genes associated with cholesterol metabolism in rats. Exp Biol Med (Maywood), 229:787-92.
40. Harris MI. 1991. Hypercholesterolemia in diabetes and glucose intolerance in the US population. Diabetes Care, 14:366-74.
41. He J, Streiffer RH, Muntner P, et al. 2004. Effect of dietary fiber intake on blood pressure: a randomized, double-blind, placebo-controlled trial. J Hypertens, 22:73-80.
42. Hiller G, Sternby M, Sundler R, et al. 2000. Phosphatidylinositol 3-kinase in zymosan- and bacteria-induced signalling to mobilisation of arachidonic acid in macrophages. Biochim Biophys Acta, 1485:163-72.
43. Hobbs FD. 2006. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. Int J Cardiol, 110:137-45.
44. Hoenig MR. 2008. Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag, 4:143-56.
45. Hsu MJ, Lee SS, Lin WW. 2002. Polysaccharide purified from Ganoderma lucidum inhibits spontaneous and Fas-mediated apoptosis in human neutrophils through activation of the phosphatidylinositol 3 kinase/Akt signaling pathway. J Leukoc Biol, 72:207-16.
46. Hughes SA, Shewry PR, Gibson GR, et al. (2008) In vitro fermentation of oat and barley derived beta-glucans by human faecal microbiota. FEMS Microbiol Ecol, 64:482-93.
47. Hyoung Lee D, Ho Kim J, Sik Park J, et al. 2004. Isolation and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from the edible mushroom Tricholoma giganteum. Peptides, 25:621-7.
48. James WP. 2008. The epidemiology of obesity: the size of the problem. J Intern Med, 263:336-52.
49. Jenkins AL, Jenkins DJ, Zdravkovic U, et al. 2002. Depression of the glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Eur J Clin Nutr, 56:622-8.
50. Jeppesen J, Hein HO, Suadicani P, et al. 2003. High triglycerides/low high-density lipoprotein cholesterol, ischemic electrocardiogram changes, and risk of ischemic heart disease. Am Heart J, 145:103-8.
51. Kabir Y, Kimura S. 1989. Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo), 35:91-4.
52. Kabir Y, Kimura S, Tamura T. 1988. Dietary effect of Ganoderma lucidum mushroom on blood pressure and lipid levels in spontaneously hypertensive rats (SHR). J Nutr Sci Vitaminol (Tokyo), 34:433-8.
53. Kabir Y, Yamaguchi M, Kimura S. 1987. Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo), 33:341-6.
54. Kannel WB, McGee DL. 1979. Diabetes and cardiovascular risk factors: the Framingham study. Circulation, 59:8-13.
55. Kapur NK, Ashen D, Blumenthal RS. 2008. High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag, 4:39-57.
56. Karmally W, Montez MG, Palmas W, et al. 2005. Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. J Am Diet Assoc, 105:967-70.
57. Karnik AA, Fields AV, Shannon RP. 2007. Diabetic cardiomyopathy. Curr Hypertens Rep, 9:467-73.
58. Katagiri H, Asano T, Ishihara H, et al. 1996. Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J Biol Chem, 271:16987-90.
59. Kenyon AJ, Michaels EB. 1983. Modulation of early cellular events in wound healing in mice. Am J Vet Res, 44:340-3.
60. Keogh GF, Cooper GJ, Mulvey TB, et al. 2003. Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am J Clin Nutr, 78:711-8.
61. Keogh JB, Lau CW, Noakes M, et al. 2007. Effects of meals with high soluble fibre, high amylose barley variant on glucose, insulin, satiety and thermic effect of food in healthy lean women. Eur J Clin Nutr, 61:597-604.
62. Kerckhoffs DA, Brouns F, Hornstra G, et al. 2002. Effects on the human serum lipoprotein profile of beta-glucan, soy protein and isoflavones, plant sterols and stanols, garlic and tocotrienols. J Nutr, 132:2494-505.
63. Kerckhoffs DA, Hornstra G, Mensink RP. 2003. Cholesterol-lowering effect of beta-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when beta-glucan is incorporated into bread and cookies. Am J Clin Nutr, 78:221-7.
64. Kibos A, Campeanu A, Tintoiu I. 2007. Pathophysiology of coronary artery in-stent restenosis. Acute Card Care, 9:111-9.
65. Kiho T, Kobayashi T, Morimoto H, et al. 2000. Structural features of an anti-diabetic polysaccharide (TAP) from Tremella aurantia. Chem Pharm Bull (Tokyo), 48:1793-5.
66. Kiho T, Morimoto H, Sakushima M, et al. 1995. Polysaccharides in fungi. XXXV. Anti diabetic activity of an acidic polysaccharide from the fruiting bodies of Tremella aurantia. Biol Pharm Bull, 18:1627-9.
67. Kim JK, Kim YJ, Fillmore JJ, et al. 2001. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest, 108:437-46.
68. Kim YW, Kim KH, Choi HJ, et al. 2005. Anti-diabetic activity of beta-glucans and their enzymatically hydrolyzed oligosaccharides from Agaricus blazei. Biotechnol Lett, 27:483-7.
69. Kissebah AH, Freedman DS, Peiris AN. 1989. Health risks of obesity. Med Clin North Am, 73:111-38.
70. Klag MJ, Whelton PK, Randall BL, et al. 1996. Blood pressure and endstage renal disease in men. N Engl J Med, 334:13-8.
71. Klein R. 1995. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 18:258-68.
72. Kreier F, Kalsbeek A, Sauerwein HP, et al. 2007. "Diabetes of the elderly" and type 2 diabetes in younger patients: possible role of the biological clock. Exp Gerontol, 42:22-7.
73. Laakso M. 1996. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Ann Med, 28:341-5.
74. +) and insulin-mediated glucose uptake. Curr Opin Pharmacol, 8:339-45.
75. Lee JY, Kim JY, Lee YG, et al. 2008. Molecular mechanism of macrophage activation by exopolysaccharides from liquid culture of Lentinus edodes. J Microbiol Biotechnol, 18:355-64.
76. Li B, Allendorf DJ, Hansen R, et al. 2006. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol, 177:1661-9.
77. Li C, Ha T, Kelley J, et al. 2004. Modulating Toll-like receptor mediated signaling by (1→3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res, 61:538-47.
78. Lia A, Hallmans G, Sandberg AS, et al. 1995. Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Am J Clin Nutr, 62:1245-51.
79. Liuba P, Pesonen E. 2005. Infection and early atherosclerosis: does the evidence support causation? Acta Paediatr, 94:643-51.
80. Lo HC, Tsai FA, Wasser SP, et al. 2006. Effects of ingested fruiting bodies, submerged culture biomass, and acidic polysaccharide glucuronoxylomannan of Tremella mesenterica Retz:Fr. on glycemic responses in normal and diabetic rats. Life Sci, 78:1957-66.
81. Lucas EH, Byerrum RU, Clarke DA, et al. 1958. Production of oncostatic principles in vivo and in vitro by species of the genus Calvatia. Antibiot Annu, 6:493-6.
82. Ludwig DS. 2003. Dietary glycemic index and the regulation of body weight. Lipids, 38:117-21.
83. Maki KC, Galant R, Samuel P, et al. 2007. Effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur J Clin Nutr, 61:786-95.
84. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell, 129:1261-74.
85. Marlett JA. 1997. Sites and mechanisms for the hypocholesterolemic actions of soluble dietary fiber sources. Adv Exp Med Biol, 427:109-21.
86. Martin SS, Haruta T, Morris AJ, et al. 1996. Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. J Biol Chem, 271:17605-8.
87. Mayell M. 2001. Maitake extracts and their therapeutic potential. Altern Med Rev, 6:48-60.
88. McIntosh M, Stone BA, Stanisich VA. 2005. Curdlan and other bacterial (1→3)-beta-D-glucans. Appl Microbiol Biotechnol, 68:163-73.
89. Mineo C, Yuhanna IS, Quon MJ, et al. 2003. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem, 278:9142-9.
90. Mokdad AH, Ford ES, Bowman BA, et al. 2003. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA, 289:76-9.
91. Naumann E, Van Rees AB, Onning G, et al. 2006. Beta-glucan incorporated into a fruit drink effectively lowers serum LDL-cholesterol concentrations. Am J Clin Nutr, 83:601-5.
92. Ng Y, Ramm G, Lopez JA, et al. 2008. Rapid activation of Akt2 is sufficient to stimulate GLUT4 translocation in 3T3-L1 adipocytes. Cell Metab, 7:348-56.
93. Nilsson LM, Abrahamsson A, Sahlin S, et al. 2007. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun, 357:707-11.
94. Okada T, Kawano Y, Sakakibara T, et al. 1994. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem, 269:3568-73.
95. Olefsky JM. 1981. LIlly lecture 1980. Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes, 30:148-62.
96. Olsson S, Sundler R. 2007. The macrophage beta-glucan receptor mediates arachidonate release induced by zymosan: essential role for Src family kinases. Mol Immunol, 44:1509-15.
97. Portera CA, Love EJ, Memore L, et al. 1997. Effect of macrophage stimulation on collagen biosynthesis in the healing wound. Am Surg, 63:125-31.
98. Pyorala K, Laakso M, Uusitupa M. 1987. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev, 3:463-524.
99. Regina A, Bird A, Topping D, et al; 2006. High-amylose wheat generated by RNA interference improves indices of large-bowel health in rats. Proc Natl Acad Sci U S A, 103:3546-51.
100. Reyna-Villasmil N, Bermudez-Pirela V, Mengual-Moreno E, et al. 2007. Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia. Am J Ther, 14:203-12.
101. Rice PJ, Kelley JL, Kogan G, et al. 2002. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-beta-D-glucans. J Leukoc Biol, 72:140-6.
102. Rother KI. 2007. Diabetes treatment - bridging the divide. N Engl J Med, 356:1499-501.
103. Sadiq Butt M, Tahir-Nadeem M, Khan MK, et al. 2008. Oat: unique among the cereals. Eur J Nutr, 47:68-79.
104. Sanchez D, Muguerza B, Moulay L, et al. 2008. Highly methoxylated pectin improves insulin resistance and other cardiometabolic risk factors in Zucker fatty rats. J Agric Food Chem, 56:3574-81.
105. Saris WH. 2003. Glycemic carbohydrate and body weight regulation. Nutr Rev, 61:S10-6.
106. Sasaki H, Ogawa K, Shimizu M, et al. 2007. The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats. Int Heart J, 48:623-35.
107. Schinner S, Scherbaum WA, Bornstein SR, et al. 2005. Molecular mechanisms of insulin resistance. Diabet Med, 22:674-82.
108. Schmid F, Stone BA, McDougall BM, et al. 2001. Structure of epiglucan, a highly side-chain/branched (1 → 3; 1 → 6)-beta-glucan from the micro fungus Epicoccum nigrum Ehrenb. ex Schlecht. Carbohydr Res, 331:163-71.
109. Schulze MB, Rimm EB, Shai I, et al. 2004. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care, 27:1680-7.
110. Shepherd PR, Nave BT, Siddle K. 1995. Involvement of PI 3-kinase in stimulation of glucose transport and recruitment of transferrin receptors in 3T3-L1 adipocytes. Biochem Soc Trans, 23:201S.
111. Shimizu C, Kihara M, Aoe S, et al. 2008. Effect of high beta-glucan barley on serum cholesterol concentrations and visceral fat area in Japanese men-A randomized, double-blinded, placebo-controlled trial. Plant Foods Hum Nutr, 63:21-5.
112. Shulman GI. 2000. Cellular mechanisms of insulin resistance. J Clin Invest, 106:171-6.
113. Siperstein MD. 1992. Diabetic ketoacidosis and hyperosmolar coma. Endocrinol Metab Clin North Am, 21:415-32.
114. Stamler J, Vaccaro O, Neaton JD, et al. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-44.
115. Stolk RP, Van Schooneveld MJ, Cruickshank JK, et al. 2008. Retinal vascular lesions in patients of Caucasian and Asian origin with type 2 diabetes: baseline results from the ADVANCE Retinal Measurements (AdRem) study. Diabetes Care, 31:708-13.
116. Sutherland C, O'Brien RM, Granner DK. 1995. Phosphatidylinositol 3-kinase, but not p70/p85 ribosomal S6 protein kinase, is required for the regulation of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by insulin. Dissociation of signaling pathways for insulin and phorbol ester regulation of PEPCK gene expression. J Biol Chem, 270:15501-6.
117. Talpur N, Echard B, Dadgar A, et al. 2002a. Effects of Maitake mushroom fractions on blood pressure of Zucker fatty rats. Res Commun Mol Pathol Pharmacol, 112:68-82.
118. Talpur N, Echard BW, Yasmin T, et al. 2003. Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-hydroxycitric acid on the metabolic syndrome in aged diabetic Zucker fatty rats. Mol Cell Biochem, 252:369-77.
119. Talpur NA, Echard BW, Fan AY, et al. 2002b. Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains. Mol Cell Biochem, 237:129-36.
120. Tapola N, Karvonen H, Niskanen L, et al. 2005. Glycemic responses of oat bran products in type 2 diabetic patients. Nutr Metab Cardiovasc Dis, 15:255-61.
121. Tappy L, Gugolz E, Wursch P. 1996. Effects of breakfast cereals containing various amounts of beta-glucan fibers on plasma glucose and insulin responses in NIDDM subjects. Diabetes Care, 19:831-4.
122. Theuwissen E, Mensink RP. 2007. Simultaneous intake of beta-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. J Nutr, 137:583-8.
123. Trinidad AG, de la Puerta ML, Fernandez N, et al. 2006. Coupling of C3bi to IgG inhibits the tyrosine phosphorylation signaling cascade down-stream Syk and reduces cytokine induction in monocytes. J Leukoc Biol, 79, 1073-82.
124. Tschritter O, Fritsche A, Thamer C, et al. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 52:239-43.
125. Turner RC, Millns H, Neil HA, et al. 1998 Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 316:823-8.
126. Underhill DM, Rossnagle E, Lowell CA, et al. 2005. Dectin-I activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood, 106:2543-50.
127. Van Horn L, Moag-Stahlberg A Liu KA, et al. 1991. Effects on serum lipids of adding instant oats to usual American diets. Am J Public Health, 81:183-8.
128. Watson RT, Pessin JE. 2001. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res, 56:175-93.
129. Wei D, Zhang L, Williams DL, et al. 2002. Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen, 10:161-8.
130. [WHO] World Health Organization. 2008. Global strategy on diet, physical activity and health: diabetes. Accessed on May 4, 2008. URL: http://www.who.int/dietphysicalactivity/publications/facts/diabetes/en/ index.html.
131. Williams DL, Di Luzio NR. 1980. Glucan-induced modification of murine viral hepatitis. Science, 208:67-9.
132. Yamauchi T, Kamon J, Waki H, et al. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 7:941-6.